'Activity dependent' presentation slideshows

Synaptogenesis

597 views • 40 slides

Synaptogenesis

401 views • 40 slides

Synaptic plasticity: Introduction

516 views • 37 slides

High/Correlated activity

Magic. Magic. LTP. LTD. High/Correlated activity. Low/uncorrelated activity. High NMDA-R activation. Moderate NMDA-R activation. High Calcium. Moderate Calcium. LTP. LTD. What changes during synaptic plasticity?

390 views • 32 slides

High/Correlated activity

Magic. Magic. LTP. LTD. High/Correlated activity. Low/uncorrelated activity. High NMDA-R activation. Moderate NMDA-R activation. High Calcium. Moderate Calcium. LTP. LTD. What changes during the expression of synaptic plasticity? Is expression pre or post-synaptic

388 views • 30 slides

Activity-Dependent Development II April 25, 2007 Mu-ming Poo

Activity-Dependent Development II April 25, 2007 Mu-ming Poo. The neurotrophin hypothesis Maps in somatic sensory and motor cortices Development of retinotopic map Reorganization of cortical maps following sensory deprivation Synaptic basis of cortical plasticity --- LTP and LTD

336 views • 19 slides

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions. Tom Sutula, MD, PhD Department of Neurology, University of Wisconsin Chief Scientific Officer, NeuroGenomex, Inc. The novel mechanism of 2DG: why 2DG is a glycolytic inhibitor.

438 views • 18 slides

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions

2DG - a glucose analogue and glycolytic inhibitor with anticonvulsant and antiepileptic actions. Tom Sutula, MD, PhD Department of Neurology, University of Wisconsin Chief Scientific Officer, NeuroGenomex, Inc. The novel mechanism of 2DG: why 2DG is a glycolytic inhibitor.

280 views • 18 slides

GW610

118 views • 1 slides